FILING ANALYSIS · TUESDAY, NOVEMBER 3
ZEVRA THERAPEUTICS, INC. ZVRA — 8-K: Results of Operations and Financial Condition
neutral
Zevra Therapeutics reported a 45% increase in total net revenue to $37.8 million for Q3 2026, driven by $34.0 million in revenue from MIPLYFFA, and a strong cash position of $270.9 million, but the filing lacks a significant surprise to drive a large price move
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →